A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.
Completed
West China Hospital
Phase 1
This is a phase I study evaluating tolerability, pharmacokinetics, and preliminary efficacy
of HC-1119 in patients with metastatic castration-resistant prostate cancer. The study
objective is to study the tolerability, safety, and dose-limiting toxicities (DLT) of HC-1119
in patients with mCRPC.
A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.
Completed
Hinova Pharmaceuticals Inc.
Phase 1
This is a phase I study evaluating tolerability, pharmacokinetics, and preliminary efficacy
of HC-1119 in patients with metastatic castration-resistant prostate cancer. The study
objective is to study the tolerability, safety, and dose-limiting toxicities (DLT) of HC-1119
in patients with mCRPC.
A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.
Completed
Sichuan Haisco Pharmaceutical Group Co., Ltd.
Phase 1
This is a phase I study evaluating tolerability, pharmacokinetics, and preliminary efficacy
of HC-1119 in patients with metastatic castration-resistant prostate cancer. The study
objective is to study the tolerability, safety, and dose-limiting toxicities (DLT) of HC-1119
in patients with mCRPC.
A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics
Completed
Hinova Pharmaceuticals Inc.
Phase 1
This is a phase I study evaluating HC-1119 single-dose pharmacokinetics and effect of food on
its pharmacokinetics in healthy Chinese adults. The study primary objective is to evaluate
the HC-1119 pharmacokinetic characteristics and the effect of food on its pharmacokinetics in
healthy Chinese males, subsequent to a single oral administration of HC-1119 with different
doses in healthy Chinese males.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
